‘A stretch of normal life’ as myeloma patients enter uncharted era
How one patient traveled to China to pursue an experimental therapy that changed what was possible in multiple myeloma.
Cellular Therapy
Multiple Myeloma
News
ASH 2025
Cellular Therapy
Leukemia
Acute Myeloid Leukemia
Dr. Gwen Nichols, of Blood Cancer United, talks financial toxicity in blood cancer care
Gwen Nichols, MD, chief medical officer of Blood Cancer United, discusses generational financial toxicity in oncology, particularly in pediatric acute leukemia care, and
Cellular Therapy
Multiple Myeloma
SOHO Insider Podcast
Dr. Thomas Martin interviews 1st US patient treated with cilta-cel
In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient
ASH 2025
Cellular Therapy
Multiple Myeloma
News
Earlier lines of cilta-cel linked to better immune fitness in myeloma
Samir Parekh, MBBS, a professor of medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai,
ASH 2025
Triplet therapy shows efficacy, tolerability, and transplant potential in BPDCN
Tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy shows efficacy, tolerability, and transplant potential in patients with blastic plasmacytoid dendritic cell neoplasm, according to
ASH 2025
Cellular Therapy
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Aggressive B-Cell Lymphomas
Dr. Avalos highlights ASH 2025 takeaways, the future of blood cancer
Belinda Avalos, MD, professor of medicine and a senior advisor to the president of Atrium Health Levine Cancer, discusses the biggest highlights from
Lymphoma Roundtable
Lymphoma
Roundtable Discussions
Video Interviews
What are the areas of unmet needs in large cell lymphoma?
In this video, the group discusses unmet needs in large cell lymphoma and novel agents, including the CELLMod golcadomide.
ASH 2025
Updated phase 3 VERIFY results confirm rusfertide significantly improves PV outcomes over SOC
In patients with polycythemia vera receiving standard of care therapy, treatment with rusfertide continued to yield a statistically significant reduction in the mean
ASH 2025
Lymphoma
Indolent B-Cell Lymphomas
Epcoritamab triplet may set new standard in 2L follicular lymphoma
Epcoritamab in combination with rituximab and lenalidomide has the potential to be the new standard of care in patients with second-line follicular lymphoma,
Multiple Myeloma
News
Extramedullary disease in MM associated with severe toxicities following BCMA-targeted CAR T-cell therapy
Extramedullary disease (EMD) in multiple myeloma (MM) is associated with significantly higher rates of severe toxicity following B-cell maturation antigen (BCMA)-targeted CAR T-cell